taurine has been researched along with Alcohol-Related Disorders in 34 studies
Alcohol-Related Disorders: Disorders related to or resulting from abuse or misuse of alcohol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acamprosate has been available in the United States for treating alcohol use disorders (AUDs) for nearly a decade, yet few studies have examined its use within AUD treatment organizations." | 2.79 | Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders. ( Knudsen, HK; Roman, PM, 2014) |
| "Acamprosate is a widely utilized, efficacious treatment for relapse prevention in alcohol dependent patients." | 2.74 | The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. ( Franck, J; Hammarberg, A; Jayaram-Lindström, N; Nylander, I; Reid, MS; Zhou, Q, 2009) |
| " Factors such as dosing frequency, potential adverse events, and availability of treatments may guide medication choice." | 2.50 | Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. ( Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R, 2014) |
| "Acamprosate appears to be an effective and safe treatment strategy for supporting continuous abstinence after detoxification in alcohol dependent patients." | 2.46 | Acamprosate for alcohol dependence. ( Hackl-Herrwerth, A; Lehert, P; Leucht, S; Rösner, S; Soyka, M; Vecchi, S, 2010) |
| "Medications for treating alcohol dependence primarily have been adjunctive interventions, and only three medications--disulfiram, naltrexone, and acamprosate--are approved for this indication by the U." | 2.43 | Medications for treating alcohol dependence. ( Williams, SH, 2005) |
| "Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004." | 1.42 | Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects. ( Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Hinton, DJ; Ho, AM; Karpyak, VM; Nam, HW; Prieto, ML; Weinshilboum, RM, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (38.24) | 29.6817 |
| 2010's | 21 (61.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lyon, J | 1 |
| Soyka, M | 3 |
| Zindel, LR | 1 |
| Kranzler, HR | 2 |
| Knudsen, HK | 2 |
| Roman, PM | 2 |
| Jonas, DE | 1 |
| Amick, HR | 1 |
| Feltner, C | 1 |
| Bobashev, G | 1 |
| Thomas, K | 1 |
| Wines, R | 1 |
| Kim, MM | 1 |
| Shanahan, E | 1 |
| Gass, CE | 1 |
| Rowe, CJ | 1 |
| Garbutt, JC | 1 |
| Testino, G | 1 |
| Leone, S | 1 |
| Borro, P | 1 |
| Witkiewitz, K | 2 |
| Vowles, KE | 1 |
| McCallion, E | 1 |
| Frohe, T | 1 |
| Kirouac, M | 1 |
| Maisto, SA | 1 |
| Mark, TL | 1 |
| Lubran, R | 1 |
| McCance-Katz, EF | 1 |
| Chalk, M | 1 |
| Richardson, J | 1 |
| Nam, HW | 1 |
| Karpyak, VM | 1 |
| Hinton, DJ | 1 |
| Geske, JR | 1 |
| Ho, AM | 1 |
| Prieto, ML | 1 |
| Biernacka, JM | 1 |
| Frye, MA | 1 |
| Weinshilboum, RM | 1 |
| Choi, DS | 1 |
| Yumoto, Y | 1 |
| Higuchi, S | 1 |
| Helton, SG | 1 |
| Lohoff, FW | 1 |
| Bramness, JG | 1 |
| Mann, K | 1 |
| Wurst, FM | 1 |
| Harris, AH | 1 |
| Bowe, T | 1 |
| Hagedorn, H | 1 |
| Nevedal, A | 1 |
| Finlay, AK | 1 |
| Gidwani, R | 1 |
| Rosen, C | 1 |
| Kay, C | 1 |
| Christopher, M | 1 |
| Crits-Christoph, P | 1 |
| Markell, HM | 1 |
| Gibbons, MB | 1 |
| Gallop, R | 1 |
| Lundy, C | 1 |
| Stringer, M | 1 |
| Gastfriend, DR | 1 |
| von der Goltz, C | 1 |
| Vengeliene, V | 2 |
| Bilbao, A | 1 |
| Perreau-Lenz, S | 1 |
| Pawlak, CR | 1 |
| Kiefer, F | 1 |
| Spanagel, R | 2 |
| Hammarberg, A | 1 |
| Nylander, I | 1 |
| Zhou, Q | 1 |
| Jayaram-Lindström, N | 1 |
| Reid, MS | 1 |
| Franck, J | 1 |
| Zarkin, GA | 1 |
| Bray, JW | 1 |
| Aldridge, A | 1 |
| Mills, M | 1 |
| Cisler, RA | 1 |
| Couper, D | 1 |
| McKay, JR | 1 |
| O'Malley, S | 1 |
| Rösner, S | 1 |
| Hackl-Herrwerth, A | 1 |
| Leucht, S | 1 |
| Lehert, P | 1 |
| Vecchi, S | 1 |
| Hunter-Reel, D | 1 |
| Zweben, A | 1 |
| Clark, DB | 1 |
| Maisel, NC | 1 |
| Blodgett, JC | 1 |
| Wilbourne, PL | 1 |
| Humphreys, K | 1 |
| Finney, JW | 1 |
| Kenna, GA | 1 |
| McGeary, JE | 1 |
| Swift, RM | 1 |
| Williams, SH | 1 |
| Morley, KC | 1 |
| Teesson, M | 1 |
| Reid, SC | 1 |
| Sannibale, C | 1 |
| Thomson, C | 1 |
| Phung, N | 1 |
| Weltman, M | 1 |
| Bell, JR | 1 |
| Richardson, K | 1 |
| Haber, PS | 1 |
| Swift, R | 1 |
| McDonough, KP | 1 |
| Peterson, AM | 1 |
| Green, AI | 1 |
| Drake, RE | 1 |
| Brunette, MF | 1 |
| Noordsy, DL | 1 |
| Berglund, M | 1 |
| Gorelick, D | 1 |
| Hesselbrock, V | 1 |
| Johnson, BA | 1 |
| Möller, HJ | 1 |
| Fiellin, DA | 1 |
| Reid, MC | 1 |
| O'Connor, PG | 1 |
| Tedeschi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep: A Randomized, Double-Blind, Placebo- Controlled Study[NCT05458609] | Phase 3 | 14 participants (Anticipated) | Interventional | 2023-02-09 | Enrolling by invitation | ||
| In Hospital Administration of Extended-Release Naltrexone for Alcohol Use Disorder: A Pilot Study of Feasibility and Acceptability[NCT05087771] | Phase 4 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to no longer randomized, drug being offered to all patients) | ||
| The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.[NCT03018236] | Phase 4 | 100 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| A Pilot Study of N-acetylcysteine for Alcohol Use Disorder[NCT04964843] | Phase 2 | 0 participants (Actual) | Interventional | 2023-04-30 | Withdrawn (stopped due to Null results were posted from a neurometabolite study and a recent trial for AUD. Study may resume if more positive data emerge.) | ||
| Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse[NCT02423772] | 37 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Participatory System Dynamics vs Audit and Feedback: A Cluster Randomized Trial of Mechanisms of Implementation Change to Expand Reach of Evidence-based Addiction and Mental Health Care[NCT04356274] | 720 participants (Anticipated) | Interventional | 2019-02-01 | Enrolling by invitation | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Auricular Percutaneous Electrical Neural Field Stimulation in Short-Term Treatment of Alcohol Dependence- Neurohaemodynamic Correlates and Feasibility Study[NCT04106739] | 44 participants (Actual) | Interventional | 2019-10-20 | Completed | |||
| Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial[NCT02771925] | Phase 4 | 25 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to poor compliance of patients in the study.) | ||
| Phase Four Randomized, Multicentre, Open-Label, Comparative Trial Of Disulfiram, Nalterexone And Acamprosate In The Treatment Of Alcohol Dependence[NCT00435435] | Phase 4 | 243 participants | Interventional | 2000-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
15 reviews available for taurine and Alcohol-Related Disorders
| Article | Year |
|---|---|
Pharmacotherapy of alcohol use disorders: seventy-five years of progress.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Fructose; Humans; Hypnotics | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; R | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking | 2014 |
[Pharmacological therapies for alcohol use disorder in Japan].
Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Sy | 2015 |
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressi | 2015 |
Acamprosate for alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Diarrhea; Humans; Placebo Effect; | 2010 |
New pharmacological treatment strategies for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Disulfiram; Drugs, Investigatio | 2013 |
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Ethanol; Humans; Inactivation, Metabolic | 2013 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Tria | 2004 |
Medications for treating alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dos | 2005 |
Emerging approaches to managing alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Brain; Disulfiram; Dru | 2007 |
Improving adherence in patients with alcohol dependence: a new role for pharmacists.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Disulfiram; Humans; Na | 2007 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Di | 2008 |
New therapies for alcohol problems: application to primary care.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Top | 2000 |
Naltrexone and acamprosate. Using new drugs for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Australia; Clinical Trials as Topic; Fem | 2001 |
5 trials available for taurine and Alcohol-Related Disorders
| Article | Year |
|---|---|
Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Cross-Sectional Studies; Health Plan Imp | 2014 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therap | 2015 |
The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin.
Topics: Acamprosate; Adrenocorticotropic Hormone; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Diso | 2009 |
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Thera | 2012 |
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety; Australia; Depressive Di | 2006 |
14 other studies available for taurine and Alcohol-Related Disorders
| Article | Year |
|---|---|
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic | 2017 |
Review: In alcohol use disorders, acamprosate is more effective for inducing abstinence while naltrexone is more effective for reducing heavy drinking and craving.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2013 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination | 2015 |
Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biomarkers; Glutamic Acid; Humans; Tauri | 2015 |
The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Humans; Insurance Carriers; Longitudinal | 2016 |
Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe.
Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Europe; | 2016 |
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Hum | 2016 |
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Delayed-Action Preparations; Fema | 2016 |
Cue-induced alcohol-seeking behaviour is reduced by disrupting the reconsolidation of alcohol-related memories.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Anisomycin; Behavior, Addictive | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism | 2009 |
The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
Topics: Acamprosate; Accidents, Traffic; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Co | 2010 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorde | 2012 |
Alcohol dependence and pharmacologic treatment. Introduction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Humans; Naltrexone; Taurine; | 2007 |
Schizophrenia and co-occurring substance use disorder.
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (P | 2007 |